VKTX – Viking Therapeutics Inc.
Viking Therapeutics, Inc.VKTX
$27.76Name : Viking Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $3,540,016,128.00
EPSttm : -5.42
Viking Therapeutics, Inc.
$27.76
2.39%$0.68
VKTX — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
19.52
Margin Of Safety %
Put/Call OI Ratio
0.22
EPS Next Q Diff
0.19
EPS Last/This Y
-2.12
EPS This/Next Y
0.11
Price
28.43
Target Price
95.32
Analyst Recom
1.19
Performance Q
-13.66
Upside
-347.3%
Beta
0.75
Ticker: VKTX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-10-13 | VKTX | 26.67 | 0.23 | 0.28 | 332742 |
| 2026-10-14 | VKTX | 25.55 | 0.23 | 0.15 | 340917 |
| 2026-10-15 | VKTX | 27.39 | 0.23 | 0.78 | 348645 |
| 2026-10-16 | VKTX | 25.17 | 0.22 | 0.59 | 354298 |
| 2026-10-19 | VKTX | 25.06 | 0.20 | 0.32 | 267087 |
| 2026-10-20 | VKTX | 26.74 | 0.20 | 0.10 | 272700 |
| 2026-10-21 | VKTX | 26.4 | 0.20 | 0.29 | 282117 |
| 2026-10-22 | VKTX | 25.82 | 0.20 | 1.40 | 287763 |
| 2026-10-23 | VKTX | 24.39 | 0.22 | 0.41 | 295975 |
| 2026-10-26 | VKTX | 24.24 | 0.22 | 0.15 | 289833 |
| 2026-10-27 | VKTX | 24.89 | 0.22 | 0.31 | 294934 |
| 2026-10-28 | VKTX | 25.36 | 0.22 | 0.38 | 298343 |
| 2026-10-29 | VKTX | 26.89 | 0.22 | 0.10 | 306276 |
| 2026-10-30 | VKTX | 27.31 | 0.22 | 0.28 | 309827 |
| 2026-11-02 | VKTX | 26.83 | 0.21 | 0.35 | 289357 |
| 2026-11-03 | VKTX | 26.09 | 0.21 | 0.32 | 292702 |
| 2026-11-04 | VKTX | 27.97 | 0.21 | 0.09 | 295650 |
| 2026-11-05 | VKTX | 25.78 | 0.21 | 0.51 | 300237 |
| 2026-11-06 | VKTX | 26.86 | 0.21 | 0.54 | 301123 |
| 2026-11-09 | VKTX | 28.99 | 0.22 | 0.16 | 292555 |
| 2026-11-10 | VKTX | 28.66 | 0.22 | 0.14 | 296696 |
| 2026-11-11 | VKTX | 28.34 | 0.22 | 0.49 | 300345 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-10-13 | VKTX | 26.66 | -31.5 | - | -4.60 |
| 2026-10-14 | VKTX | 25.48 | -31.5 | - | -4.60 |
| 2026-10-15 | VKTX | 27.40 | -31.5 | - | -4.60 |
| 2026-10-16 | VKTX | 25.17 | -31.0 | - | -4.59 |
| 2026-10-19 | VKTX | 25.05 | -31.0 | - | -4.59 |
| 2026-10-20 | VKTX | 25.05 | -31.0 | - | -4.59 |
| 2026-10-21 | VKTX | 26.72 | -31.0 | - | -4.59 |
| 2026-10-22 | VKTX | 25.83 | -31.0 | - | -4.59 |
| 2026-10-23 | VKTX | 24.39 | -31.0 | - | -4.59 |
| 2026-10-26 | VKTX | 24.24 | -30.9 | - | -4.59 |
| 2026-10-27 | VKTX | 24.88 | -30.9 | - | -4.59 |
| 2026-10-28 | VKTX | 25.38 | -30.9 | - | -4.59 |
| 2026-10-29 | VKTX | 26.91 | -30.9 | - | -4.59 |
| 2026-10-30 | VKTX | 27.31 | -30.9 | - | -4.59 |
| 2026-11-02 | VKTX | 26.83 | 2.4 | - | -5.31 |
| 2026-11-03 | VKTX | 26.11 | 2.4 | - | -5.31 |
| 2026-11-04 | VKTX | 28.00 | 2.4 | - | -5.31 |
| 2026-11-05 | VKTX | 25.77 | 2.4 | - | -5.31 |
| 2026-11-06 | VKTX | 26.86 | 2.4 | - | -5.31 |
| 2026-11-09 | VKTX | 28.98 | 2.4 | - | -5.31 |
| 2026-11-10 | VKTX | 28.67 | 2.4 | - | -5.31 |
| 2026-11-11 | VKTX | 28.43 | 2.0 | - | -5.31 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-10-13 | VKTX | -4.43 | 2.09 | 21.06 |
| 2026-10-14 | VKTX | -4.43 | 2.09 | 21.06 |
| 2026-10-15 | VKTX | -4.43 | 2.09 | 21.06 |
| 2026-10-16 | VKTX | -4.43 | 2.09 | 21.06 |
| 2026-10-19 | VKTX | -4.80 | 2.00 | 21.00 |
| 2026-10-20 | VKTX | -4.80 | 2.00 | 21.00 |
| 2026-10-21 | VKTX | -4.80 | 2.00 | 21.00 |
| 2026-10-22 | VKTX | -4.80 | 2.00 | 21.00 |
| 2026-10-23 | VKTX | -4.80 | 2.00 | 21.00 |
| 2026-10-26 | VKTX | -4.80 | 1.95 | 21.00 |
| 2026-10-27 | VKTX | -4.80 | 1.95 | 20.69 |
| 2026-10-28 | VKTX | -4.80 | 1.95 | 20.69 |
| 2026-10-29 | VKTX | -4.80 | 1.95 | 20.69 |
| 2026-10-30 | VKTX | -4.80 | 1.95 | 20.69 |
| 2026-11-02 | VKTX | -4.79 | 1.88 | 20.63 |
| 2026-11-03 | VKTX | -4.79 | 1.88 | 20.63 |
| 2026-11-05 | VKTX | -4.79 | 1.88 | 20.63 |
| 2026-11-06 | VKTX | -4.79 | 1.88 | 20.63 |
| 2026-11-09 | VKTX | -4.79 | 1.81 | 20.63 |
| 2026-11-10 | VKTX | -4.79 | 1.81 | 20.63 |
| 2026-11-11 | VKTX | -4.79 | 1.81 | 19.52 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.55
Avg. EPS Est. Current Quarter
-1.35
Avg. EPS Est. Next Quarter
-1.36
Insider Transactions
-4.79
Institutional Transactions
1.81
Beta
0.75
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
5
Growth Score
19
Sentiment Score
51
Actual DrawDown %
71.4
Max Drawdown 5-Year %
-78.9
Target Price
95.32
P/E
Forward P/E
PEG
P/S
P/B
6.16
P/Free Cash Flow
EPS
-5.41
Average EPS Est. Cur. Y
-5.31
EPS Next Y. (Est.)
-5.21
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.53
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.7
EPS 1 30Days Diff
-0.71
EBIT Estimation
◆
VKTX
Healthcare
$28.44
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
52.6
Range 1M
77.2%
Sup Dist
1.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
-64.7%
EPS NY
4.2%
52W%
25.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+235.2% upside
Upside
+235.2%
Quality
5
VKTX — P/E HistoricalBiotechnology
Viking Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 74
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
VKTX
Latest News
—
Caricamento notizie per VKTX…
stock quote shares VKTX – Viking Therapeutics Inc. Stock Price stock today
news today VKTX – Viking Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VKTX – Viking Therapeutics Inc. yahoo finance google finance
stock history VKTX – Viking Therapeutics Inc. invest stock market
stock prices VKTX premarket after hours
ticker VKTX fair value insiders trading